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ABSTRACT 26 
 27 
Study question 28 
Are the published pre-treatment and post-treatment McLernon models, predicting cumulative live birth 29 
rates (LBR) over multiple complete IVF cycles, valid in a different context? 30 
 31 
Summary answer  32 
With minor recalibration of the pre-treatment model, both McLernon models accurately predict 33 
cumulative LBR in a different geographical context and a more recent time period.  34 
 35 
What is known already  36 
Previous IVF prediction models have estimated the chance of a live birth after a single fresh embryo 37 
transfer, thereby excluding the important contribution of embryo cryopreservation and subsequent IVF 38 
cycles to cumulative LBR. In contrast, the recently developed McLernon models predict the cumulative 39 
chance of a live birth over multiple complete IVF cycles at two certain time points: a) before initiating 40 
treatment using baseline characteristics (pre-treatment model) and b) after the first IVF cycle adding 41 
treatment related information to update predictions (post-treatment model). Before implementation of 42 
these models in clinical practice, their predictive performance needs to be validated in an independent 43 
cohort.  44 
 45 
Study design, size, duration  46 
External validation study in an independent prospective cohort of 1515 Dutch women who participated in 47 
the OPTIMIST study (NTR2657) and underwent their first IVF treatment between 2011 and 2014. 48 
Participants underwent a total of 2881 complete treatment cycles, with a complete cycle defined as all 49 
fresh and frozen thawed embryo transfers resulting from one episode of ovarian stimulation. The follow 50 
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up duration was 18 months after inclusion, and the primary outcome was ongoing pregnancy leading to 51 
live birth. 52 
 53 
Participants/materials, setting, methods 54 
Model performance was externally validated up to three complete treatment cycles, using the linear 55 
predictor as described by McLernon et al. to calculate the probability of live birth. Discrimination was 56 
expressed by the c-statistic and calibration was depicted graphically in a calibration plot. In contrast to the 57 
original model development cohort, anti-Müllerian hormone (AMH), antral follicle count (AFC) and body 58 
weight were available in the OPTIMIST cohort, and evaluated as potential additional predictors for model 59 
improvement.  60 
 61 
Main results and the role of chance  62 
Applying the McLernon models to the OPTIMIST cohort, the c-statistic of the pre-treatment model was 63 
0.62 (95% confidence interval (CI) 0.59-0.64) and of the post-treatment model 0.71 (95% CI 0.69-0.74). 64 
The calibration plot of the pre-treatment model indicated slight overestimation of the cumulative LBR. To 65 
improve calibration, the pre-treatment model was recalibrated by subtracting 0.35 from the intercept. The 66 
post-treatment model calibration plot revealed accurate cumulative LBR predictions. After addition of 67 
AMH, AFC and body weight to the McLernon models, the c-statistic of the updated pre-treatment model 68 
improved slightly to 0.66 (95% CI 0.64-0.68), and of the updated post-treatment model remained at the 69 
previous level of 0.71 (95% CI 0.69-0.73). 70 
Using the recalibrated pre-treatment model, a woman aged 30 years with two years of primary infertility 71 
who starts ICSI treatment for male factor infertility has a chance of 40% of a live birth from the first 72 
complete cycle, increasing to 72% over three complete cycles. If this woman weighs 70 kilograms, has an 73 
AMH of 1.5 ng/mL and an AFC of 10 measured at the beginning of her treatment, the updated pre-74 
treatment model revises the estimated chance of a live birth to 30% in the first complete cycle and 59% 75 
over three complete cycles. If this woman then has 5 retrieved oocytes, no embryos cryopreserved and a 76 
Page 3 of 48
http://humrep.oupjournals.org
Draft Manuscript Submitted to Human Reproduction for Peer Review
4 
 
 
single fresh cleavage stage embryo transfer in her first ICSI cycle, the post-treatment model estimates the 77 
chances of a live birth at 28% and 58%, respectively. 78 
 79 
Limitations, reasons for caution 80 
Two randomised controlled trials (RCT) evaluating the effectiveness of gonadotropin dose 81 
individualisation on basis of the AFC were nested within the OPTIMIST study. The strict dosing 82 
regimens, the RCT in- and exclusion criteria and the limited follow up time of 18 months might have 83 
influenced model performance in this independent cohort. Also, consistent with the original model 84 
development study, external validation was performed using the optimistic assumption that the 85 
cumulative LBR in couples who discontinue treatment without a live birth would have been equal to that 86 
of those who continue treatment.  87 
 88 
Wider implications of the findings  89 
After national recalibration to account for geographical differences in IVF/ICSI treatment, the McLernon 90 
prediction models can be introduced as new counselling tools in clinical practice to inform patients and to 91 
complement clinical reasoning. These models are the first to offer an objective and personalised estimate 92 
of the cumulative probability of live birth over multiple complete IVF cycles.  93 
 94 
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Introduction  110 
Infertility is defined as the failure to conceive within 12 months of regular unprotected intercourse, and  111 
affects approximately one in six couples (Oakley et al., 2008; Zegers-Hochschild et al., 2017). The 112 
majority of infertile couples seek fertility care, and many of those with prolonged unresolved infertility 113 
will be treated with ART regardless of cause (Boivin et al., 2007; Datta et al., 2016). IVF and ICSI are 114 
both widely used techniques for couples with infertility. Globally more than 1.6 million annual cycles of 115 
IVF/ICSI are performed and while success rates have increased over time (Dyer et al., 2016; McLernon et 116 
al., 2016), this treatment is still not effective for all infertile couples, with live birth rates (LBR) at around 117 
25-30% per treatment cycle (Malizia et al., 2009; McLernon et al., 2016; de Neubourg et al., 2016). Since 118 
IVF/ICSI is expensive and carries several risks, the probability of a live born child should be weighed 119 
against the risks and costs of this treatment. 120 
Several prognostic models have been developed to objectively estimate the probability of a live birth after 121 
IVF/ICSI treatment (Leushuis et al., 2009; van Loendersloot et al., 2014). It is known that prediction 122 
models often perform optimistically in their development sample, even after correction by internal 123 
validation. This is caused by overfitting, which occurs when the model corresponds too closely to the 124 
development data due to the inclusion of too many predictors (Moons, Kengne, Woodward, et al., 2012). 125 
External validation in an independent cohort of women is thus essential to examine the performance and 126 
generalisability of the prediction model (Altman et al., 2009; Harrell et al., 1996). Unfortunately, most of 127 
the currently available models that predict the chance of a live birth after IVF/ICSI treatment have never 128 
been externally validated (Leushuis et al., 2009; van Loendersloot et al., 2014). Also, the majority of 129 
these models predict the probability of a live birth after a single fresh embryo transfer, excluding the 130 
important contribution of embryo cryopreservation and subsequent treatment cycles to LBR. This limits 131 
their potential as counselling tools for couples and clinicians, especially considering the increased use and 132 
improved techniques of embryo cryopreservation and frozen thawed embryo transfer cycles in recent 133 
years (Wong et al., 2014). 134 
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Three of the largest model development studies for prediction of live birth after IVF and/or ICSI 135 
treatment used data from the Human Fertilisation and Embryology Authority (HFEA) database in the UK 136 
(McLernon et al., 2016; Nelson and Lawlor, 2011; Templeton et al., 1996). Treatment and outcome data 137 
from all licenced fertility clinics within the UK have been recorded in this database since 1992. The two  138 
models developed by Templeton et al. and Nelson et al. were both externally validated, and their 139 
predictive performance was compared to one another in several studies (Arvis et al., 2012; van 140 
Loendersloot et al., 2011; Smeenk et al., 2000; Smith et al., 2015; te Velde et al., 2014). Although these 141 
models have been recommended in previous studies and used internationally to predict live birth after 142 
IVF and ICSI (Leushuis et al., 2009; Smith et al., 2015; te Velde et al., 2014), neither model predicts 143 
cumulative LBR over multiple IVF/ICSI treatment cycles including frozen thawed embryo transfer 144 
cycles.  145 
Recently, a new model was developed by McLernon et al. using the HFEA database (McLernon et al., 146 
2016). This model is the first to provide an individualised estimate of the cumulative chance of a live 147 
birth over multiple complete cycles of IVF/ICSI, with a complete cycle defined as all fresh and frozen 148 
thawed embryo transfers resulting from one episode of ovarian stimulation. For model development, data 149 
from 113 873 women and 184 269 complete cycles between 1999 and 2009 were used. Internal validation 150 
of the model showed promising results, however evaluation of the predictive performance of the model in 151 
a different geographical context using more contemporary data has yet to be performed. Additionally, a 152 
number of potential key predictors, such as measures for ovarian reserve and female body weight, were 153 
unavailable in the HFEA database and could not be included in the original model (McLernon et al., 154 
2016). 155 
The main objective of the current study was therefore to perform geographical and temporal validation of 156 
the new HFEA model by using recent data from a different country. We also wanted to determine whether 157 
inclusion of additional parameters, such as female body weight and ovarian reserve test results i.e. antral 158 
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follicle count (AFC) and anti-Müllerian hormone (AMH), could improve the predictive performance of 159 
the model.  160 
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Materials and methods  161 
Data sources  162 
External validation was performed on data from the OPTIMIST study (van Tilborg, Oudshoorn, et al., 163 
2017). This multicentre prospective cohort study included 1515 women from 25 infertility centres in the 164 
Netherlands between May 2011 and May 2014. Participants were younger than 44 years of age, had 165 
regular menstrual cycles and no significant uterine or ovarian abnormalities on transvaginal ultrasound. 166 
Women with polycystic ovarian syndrome, metabolic or endocrine abnormalities or undergoing oocyte 167 
donation were excluded. All participants were included before their first IVF/ICSI cycle, or the first cycle 168 
after a previous live birth. The primary outcome was ongoing pregnancy, achieved within 18 months of 169 
follow up, and resulting in live birth. Ethical approval for the OPTIMIST study was obtained from the 170 
Institutional Review Board of the University Medical Centre Utrecht (MEC 10-273), and all participants 171 
provided written informed consent. A more detailed description of study procedures and results were 172 
reported previously (Oudshoorn et al., 2017; van Tilborg et al., 2012; van Tilborg, Oudshoorn, et al., 173 
2017; van Tilborg, Torrance, et al., 2017).  174 
McLernon model 175 
The McLernon model consists of two clinical prediction models to estimate the individualised cumulative 176 
chance of a live birth over a maximum of six complete treatment cycles. Before initiating treatment, the 177 
pre-treatment model predicts the probability of a live birth from both fresh and frozen thawed embryo 178 
transfers based on couple characteristics and the use of IVF or ICSI. Included predictors are: female age 179 
(years), duration of infertility (years), previous pregnancy, causes of infertility (tubal factor, anovulation, 180 
male factor, unexplained infertility), type of treatment (IVF or ICSI) and treatment year (see 181 
Supplementary Text 1).  182 
After the first fresh treatment cycle, treatment specific characteristics from this cycle are added in the 183 
post-treatment model to update the predicted probability. Added predictors are: number of oocytes, 184 
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cryopreservation of embryos, and the number and stage of embryos at the first fresh embryo transfer 185 
(single, double or triple embryo transfer; blastocyst or cleavage stage). All causes of infertility are 186 
excluded as predictors in the post-treatment model, except for tubal factor (see Supplementary Text 2). 187 
For women with zero oocytes collected in the first cycle, a separate post-treatment model is available. 188 
To predict the probability of a live birth in the ith cycle, assuming no live birth occurred in the previous 189 
cycle(s), complete cycle number is included in both models as a discrete time variable. A complete cycle 190 
includes all fresh and frozen thawed embryo transfers resulting from one episode of ovarian stimulation. 191 
With the predicted probability of a live birth per subsequent complete cycle, the cumulative probability of 192 
a live birth can be calculated up to six complete cycles (see Supplementary Text 1 and 2).  193 
Statistical analysis 194 
Nine predictor variables had missing values (Table I). The proportion of missing values was low (< 195 
2.5%), except for AMH (11.2%). During the OPTIMIST study, blood sampling was performed on the day 196 
of randomisation. Logistic issues prevented blood sampling in some cases, thus compromising the ability 197 
to undertake post-hoc measurements of AMH in the total population. As the reasons for missing values 198 
were considered to be unrelated to the AMH value itself or the measurement, these were defined as 199 
missing (completely) at random.  200 
Multiple imputation was applied for predictors with missing values in the OPTIMIST database (Sterne et 201 
al., 2009). In this process 10 imputed datasets were created using a multivariate imputation by chained 202 
equations (MICE) algorithm (van Buuren and Groothuis-Oudshoorn, 2011). Predicted probabilities for a 203 
live birth were calculated on each imputed dataset, using the predictors and parameter-estimates of both 204 
the pre-treatment model as well as the post-treatment model as described by McLernon et al 2016 205 
(McLernon et al., 2016). In accordance with the original models, the variables female age, treatment year 206 
and number of oocytes were treated with restricted cubic splines in the validation process. The separate 207 
post-treatment model for women with zero oocytes collected in the first treatment cycle was not validated 208 
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in this study, as the number of women for this analysis was too low in the OPTIMIST database. 209 
Cumulative probabilities were calculated up to three complete IVF/ICSI cycles, as most couples in the 210 
Netherlands only have three treatment cycles due to the current reimbursement policy. Also, the 211 
OPTIMIST follow up period was 18 months, reducing the number of women with more than three 212 
treatment cycles. The validation process was performed ten times on each of the imputed datasets and 213 
separate results were pooled using Rubin’s rules (Rubin, 2004). 214 
The predictive performance of the McLernon models was evaluated in terms of discrimination and 215 
calibration. Discrimination quantifies the ability of a model to correctly differentiate between subjects 216 
with an event and subjects without an event (Moons, Kengne, Woodward, et al., 2012). In the context of 217 
fertility treatment, it is the ability of the models to distinguish between women with a live birth and 218 
women without a live birth after IVF/ICSI treatment. It is expressed by the c-statistic or the area under the 219 
receiver operating curve (AUROC), which ranges between 0.5 and 1. A c-statistic of 1 indicates perfect 220 
discrimination, whereas a c-statistic of 0.5 represents a model with no discrimination at all. In this study, 221 
the c-statistic (and 95% CI) was calculated using the method suggested by Harrell et al. (Harrell et al., 222 
1996). 223 
Calibration describes the degree of agreement between predicted probabilities and observed outcomes 224 
(Moons, Kengne, Woodward, et al., 2012), in this context the predicted probability of a live birth and the 225 
observed LBR. Calibration can be assessed graphically by forming subgroups of patients determined by 226 
ranges of predicted probabilities, and then plotting the observed proportion of events against the mean 227 
predicted probability within these subgroups. When perfect calibration is present, the plot shows a 228 
diagonal line with a slope of one and an intercept of zero. In the current study, five equal subgroups of 229 
patients were formed. This was based on the sample size of the OPTIMIST cohort and the related 230 
precision of the point estimates in the calibration plot. Within these subgroups, the Kaplan Meier 231 
estimates of the observed cumulative LBR over three complete treatment cycles were plotted against the 232 
mean predicted probability of cumulative live birth. A smoothed line was then added in this plot using the 233 
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proportional hazard regression approach described by Harrell et al (Harrell et al., 1996). In addition to 234 
this, a systematic difference in the predicted and observed LBR was assessed by using calibration-in-the-235 
large (Steyerberg, 2009), and the intercept of the prediction models was adjusted in case a systematic 236 
over- or underestimation was present.   237 
Updating the models 238 
Following the external validation of the models, the additional value of updating the McLernon models 239 
with pre-specified new biomarkers was evaluated. AMH (ng/mL), AFC (2-10 mm) and body weight (kg) 240 
were added to the pre-treatment and post-treatment model in a multivariable logistic regression analysis, 241 
in which the linear predictor of the McLernon model was entered as a fixed variable. The final model was 242 
established using a manual backward selection process. Predictors were eliminated from the model 243 
according to the Akaike Information Criterion (AIC) (Akaike, 1974).  244 
The predictive performance of the new updated models was evaluated by calculating the c-statistic (and 245 
95% CI). To assess for overfitting, internal validation was performed by bootstrapping (Steyerberg, 246 
2009). Two hundred bootstrap samples, all of which were of the same size as the original validation 247 
sample, were created by random sampling with replacement (Harrell, 2001; Steyerberg, 2009). In each 248 
bootstrap sample, a new model was fitted with the same predictors as the updated models. The c-statistic 249 
was calculated for each of the 200 sample derived models, in both the bootstrap sample as well as the 250 
original validation cohort. The difference between these two c-statistics was calculated for each of the 200 251 
sample derived models, and averaged to give the optimism estimate. This was subtracted from the 252 
original c-statistic to obtain the optimism corrected c-statistic for the updated models.  253 
All statistical analyses were performed using R for Windows (version 3.3.2; R Foundation for Statistical 254 
Computing, Vienna, Austria).  255 
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Results  256 
Of the 1515 women included in the OPTIMIST study, four were excluded in the current study as they 257 
never started IVF/ICSI treatment. A total of 2881 IVF/ICSI cycles were performed over a period of 18 258 
months of follow up. Table I shows the patient and first cycle treatment characteristics of the OPTIMIST 259 
cohort (validation sample) and the HFEA cohort (development sample). Women included in the 260 
validation sample were about the same age as women in the development sample, but had a shorter 261 
average duration of infertility. The causes of infertility showed a similar distribution across both samples, 262 
with the exception of anovulation which rendered women ineligible for the OPTIMIST study. The 263 
treatment characteristics showed that embryo cryopreservation was more frequently performed after the 264 
first IVF/ICSI cycle in the validation sample and that these women most often had a cleavage stage single 265 
embryo transfer in the first fresh cycle, whereas women in the development sample most often had a 266 
cleavage stage double embryo transfer. No formal assessment was performed for the differences and 267 
similarities between the cohorts, as a description rather than a p-value is considered to be useful for 268 
interpretation of the models’ performance in this external validation study.  269 
The flowchart in Figure 1 shows the number of women in the OPTIMIST and HFEA cohorts who started 270 
a treatment cycle, had a live birth or discontinued treatment without having a live birth. The LBR per 271 
cycle was similar in both cohorts for the first, second and fourth treatment cycle. In the third cycle the 272 
LBR was slightly higher in the OPTIMIST cohort compared to the HFEA cohort. As few women in the 273 
OPTIMIST cohort received a fifth or sixth cycle, LBR in these cycles could not be compared. The 274 
proportion of women without a live birth that continued treatment was higher after the first and second 275 
cycle in the OPTIMIST cohort as compared to the HFEA cohort. After the third cycle, the proportion 276 
continuing treatment in the OPTIMIST cohort decreased, while it remained constant in the HFEA cohort. 277 
At the end of follow up, 52% of the women in the OPTIMIST study had a treatment related live birth. The 278 
overall LBR of the HFEA cohort was 43% over six complete IVF/ICSI cycles.  279 
Page 13 of 48
http://humrep.oupjournals.org
Draft Manuscript Submitted to Human Reproduction for Peer Review
14 
 
 
As mentioned previously, external validation of the McLernon models was performed up to three 280 
complete treatment cycles, and therefore the fourth, fifth and sixth complete treatment cycle in the 281 
OPTIMIST dataset (n=102 complete treatment cycles, n= 15 live births) were excluded from further 282 
analysis. Also, for the post-treatment model validation, women with zero oocytes collected in the first 283 
treatment cycle were excluded (n= 226 women, n = 526 complete treatment cycles, n= 82 live births) as a 284 
separate model was developed for this group of women by McLernon et al (McLernon et al., 2016). Due 285 
to the small numbers, this separate model could not be validated in this study. 286 
Discrimination and calibration 287 
In the validation sample, the pooled c-statistic for the pre-treatment model was 0.62 (95% CI 0.59-0.64) 288 
and for the post-treatment model 0.71 (95% CI 0.69-0.74). Figure 2a and 3 show the calibration plots for 289 
both original models, depicting the correlation between the observed and predicted cumulative LBR. The 290 
pre-treatment calibration plot had an intercept of -0.23 (95% CI -0.36- -0.10) and a slope of 0.98 (95% CI 291 
0.69-1.27), and the post-treatment calibration plot had an intercept of -0.01 (95% CI -0.12-0.11) and a 292 
slope of 0.97 (95% CI 0.77-1.19).  293 
The pre-treatment model systematically overestimated the cumulative LBR over three complete cycles for 294 
women in the validation sample. This is shown by a calibration curve with most of the confidence 295 
intervals under the reference line (Figure 2a), indicating significantly higher predicted probabilities than 296 
observed LBR. The calibration-in-the-large analysis confirmed this systematic overestimation with an 297 
intercept of  -0.35. To improve calibration, the pre-treatment model was thus adjusted by subtracting 0.35 298 
from the intercept of the original linear predictor, which decreased the predicted odds of a live birth by a 299 
factor of 1.42 (see Supplementary Text 3). The calibration plot of the recalibrated pre-treatment model 300 
showed improved accuracy of the predictions, with all confidence intervals overlapping the reference line 301 
(Figure 2b). In contrast to the pre-treatment model, the post-treatment model correctly estimated the 302 
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cumulative LBR in the validation sample, as is shown by a calibration plot with confidence intervals 303 
overlapping the reference line indicating no significant over- or underestimation (Figure 3).  304 
Updating of the models 305 
Addition of the biomarkers AMH, AFC and body weight to the pre-treatment and post-treatment model in 306 
a multivariable regression analysis resulted in two new updated models. The updated pre-treatment model 307 
included all three biomarkers as additional predictors for live birth. Since the relationship between both 308 
AMH and AFC with the probability of live birth was non-linear, these predictors were included using 309 
restricted cubic splines (see Supplementary Figure 1). The updated post-treatment model included only 310 
AFC and AMH as additional predictors for live birth, of which AFC was modelled by using restricted 311 
cubic splines (see Supplementary Figure 2). After internal validation of the updated models by 312 
bootstrapping, the updated pre-treatment model had a corrected c-statistic of 0.66 (95% CI 0.64-0.68) and 313 
the updated post-treatment model had a corrected c-statistic of 0.71 (95% CI 0.69-0.73). The addition of 314 
AFC, AMH and body weight thus resulted in a slight improvement of the discriminatory capacity of the 315 
pre-treatment model, while addition of AFC and AMH had no beneficial effect on the discriminative 316 
performance of the post-treatment model.  317 
Examples of model predictions 318 
Figures 4, 5 and 6 show examples of model predictions as illustration for clinical application. Figure 4 319 
presents predictions of the recalibrated pre-treatment model for couples with primary infertility caused 320 
by a male factor. Cumulative probabilities of live birth are calculated up to three complete ICSI cycles, 321 
and are differentiated by female age (30 or 40 years) and duration of infertility (2 years or 5 years). As is 322 
shown in figure 4, age is the most important predictor in the pre-treatment model. A 30-year-old woman 323 
with 2 years of infertility has a predicted probability of a live birth of 0.40 in the first ICSI cycle, 324 
increasing to 0.72 over three complete cycles. For a 40-year-old woman with 2 years of infertility, these 325 
probabilities are 0.15 and 0.32 respectively. 326 
Page 15 of 48
http://humrep.oupjournals.org
Draft Manuscript Submitted to Human Reproduction for Peer Review
16 
 
 
Figure 5 shows predictions of the updated pre-treatment model, with AMH, AFC and body weight as new 327 
predictors in the model. Predictions are presented for couples with two years of primary infertility caused 328 
by a male factor, and differentiation is based on female age (30 or 40 years), AMH (2.0 or 0.5 ng/mL) and 329 
AFC (15 or 7). In all scenarios the female body weight is 70 kilograms. A 30-year-old woman with an 330 
average ovarian reserve at the start of her first treatment – indicated by an AMH of 2.0 ng/mL and an 331 
AFC of 15 –  has a predicted probability of a live birth of 0.37 in the first cycle and 0.69 over three cycles 332 
(0.17 and 0.37 for a 40-year-old woman). If this woman has a reduced ovarian reserve – indicated by an 333 
AMH of 0.5 ng/mL and an AFC of 7 – the predicted probabilities decrease to 0.19 and 0.42, respectively 334 
(0.08 and 0.18 for a 40-year-old woman).  335 
Figure 6 shows predictions of the post-treatment model, which revises the predicted probabilities of the 336 
pre-treatment models by adding information of the first treatment cycle. Predictions are calculated for 337 
women with two years of primary, non-tubal infertility and are differentiated by female age (30 or 40 338 
years), number of oocytes (10 or 5) and embryo cryopreservation (yes or no). In all scenarios the woman 339 
received a cleavage stage single embryo transfer. The predicted probabilities of a live birth for women 340 
with a favourable prognosis – aged 30-years, 10 oocytes retrieved and cryopreserved embryos – is 0.49 in 341 
the first ICSI cycle, increasing to 0.83 over 3 complete cycles. In contrast, for women with a poorer 342 
prognosis – aged 40 years, 5 oocytes retrieved and no embryos cryopreserved – the predicted probabilities 343 
are 0.11 and 0.26, respectively.  344 
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Discussion 345 
Main findings 346 
This external validation study of the McLernon pre-treatment and post-treatment model found that, after 347 
minor recalibration of the intercept of the pre-treatment model, both models accurately predict the 348 
cumulative probability of live birth up to three complete IVF/ICSI cycles in a more contemporary cohort 349 
in another country. The discriminatory capacity of the pre-treatment model in an external cohort was 350 
limited, whereas the post-treatment model had a fair ability to discriminate between couples with and 351 
without a live birth after treatment. 352 
Strengths 353 
This study focuses on the external validation of an IVF prediction model, which is an essential but 354 
frequently overlooked step before implementation of a prediction model in clinical practice (Altman et 355 
al., 2009). In contrast to redeveloping new models for the same outcome, external validation and updating 356 
of existing models prevents the loss of scientific information by combining the information captured in 357 
the original model with information of a new patient cohort (Moons, Kengne, Grobbee, et al., 2012).  358 
Embryo cryopreservation has become an important part of IVF/ICSI treatment, and most couples have 359 
more than just one complete treatment cycle (Wong et al., 2014). Unlike previous prediction models 360 
(Leushuis et al., 2009; van Loendersloot et al., 2014), the McLernon models provide a more useful 361 
estimate of cumulative treatment success. As such, the validation of these models represents a significant 362 
step forward in creating a clinically useful tool to manage expectations and to inform decision making 363 
around IVF. 364 
This study benefits from the prospective design of the OPTIMIST study, which has ensured reliable data 365 
collection, with relatively low numbers of missing values and a low risk of selection bias. The multicentre 366 
design resulted in a highly representable cohort for Dutch fertility care. And although it is known that the 367 
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IVF/ICSI success rates vary between fertility centres, the inclusion of multiple centres will increase the 368 
generalisability and applicability of the external validation of the McLernon models within the 369 
Netherlands.  370 
Furthermore, the external validation was performed on data collected in a recent time period (2011-2014). 371 
Due to changing patient populations, new treatment protocols, improving technologies and increasing 372 
success rates over time, prediction models in reproduction medicine have no static form and should be 373 
regularly updated to optimally reflect the latest circumstances in which they are used (Altman et al., 374 
2009). As the McLernon models were developed on data collected between 1999 and 2009, data of the 375 
more recently performed OPTIMIST study were helpful to investigate if model performance was still 376 
accurate in current practice.  377 
Weaknesses 378 
This study has a number of limitations. First, the external validation involved data from a prospective 379 
cohort study within which two randomised controlled trials were embedded evaluating the effectiveness 380 
of individualised doses of gonadotropins based on AFC. Strict dosing regimens might have affected some 381 
treatment outcomes, such as cancellation rates and number of oocytes, thus influencing the predictive 382 
capacity of the models in the validation sample. However, as the OPTIMIST study found no difference 383 
between the dosing regimens on cumulative live birth rates, the impact on model performance is likely to 384 
be minimal.  385 
Second, the OPTIMIST study used strict eligibility criteria. Therefore, the validation sample does not 386 
fully represent the diversity of the patient population initiating IVF/ICSI treatment in the Netherlands. As 387 
none of the women in the validation sample were anovulatory, external validation of the models was only 388 
performed for an ovulatory population. This limits the generalisability of the models to some extent, as 389 
the original McLernon models were developed in a population which also included anovulatory women. 390 
Also, it could have had some impact on model performance. However, since anovulation had only a small 391 
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predictive value in the pre-treatment model, and the majority of couples underwent IVF/ICSI for other 392 
indications, a large impact on model performance is unlikely.  393 
Third, the OPTIMIST study had a follow up period of 18 months, leading to small numbers of women 394 
with more than three complete treatment cycles. Model performance could therefore only be reliably 395 
validated up to three complete cycles. However, most couples in the Netherlands complete a maximum of 396 
three treatment cycles which is partly due to the national reimbursement policy, but also by the high rates 397 
of embryo cryopreservation, increasing the number of embryo transfers and LBR per cycle. Therefore, 398 
model validation up to three complete cycles has particular clinical relevance for current Dutch fertility 399 
care.  400 
Last, the original McLernon prediction models were developed on linked cycle data, which were then 401 
used to estimate cumulative pregnancy chances. Therefore, these models used the optimistic assumption 402 
that the cumulative LBR in couples who discontinue IVF treatment without a live birth would have been 403 
equal to that of couples who continue further treatment cycles, after correction of predictor effects. This 404 
assumption tends to lead to overestimation of the cumulative LBR, as women with a low prognosis of 405 
achieving a live birth are generally more likely to discontinue treatment (Brandes et al., 2009; Olivius et 406 
al., 2004). Since the reasons for treatment withdrawal were unknown in the current external validation 407 
study, a similar method was used that probably resulted in some degree of overestimation of the 408 
cumulative LBR in the validation cohort. However, as the original McLernon models were developed 409 
with this approach, and the predictions for cumulative LBR over multiple complete cycles were 410 
considered to be clinically more relevant than per cycle predictions, we feel that the current method is the 411 
best option for the external validation of the McLernon models. 412 
Explanation of findings  413 
The discriminatory capacity of the pre-treatment model was markedly lower in the validation sample than 414 
in the development sample. In the development study, a c-statistic of 0.73 (95% CI 0.72-0.74) was 415 
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reported, whereas the present study found a c-statistic of 0.62 (95% CI 0.59-0.64). For the post-treatment 416 
model, the discriminatory performance in the validation sample was comparable to that in the 417 
development sample, with a c-statistic of 0.71 (95% CI 0.69-0.74) and 0.72 (95% CI 0.71-0.73) 418 
respectively (McLernon et al., 2016). As it is known that prediction models tend to perform too 419 
optimistically in the development dataset due to overfitting, some reduction in model performance is to be 420 
expected during external validation due to the differences between samples (Altman et al., 2009; Moons, 421 
Kengne, Woodward, et al., 2012). This, to some extent, also explains the lower overall performance of 422 
the pre-treatment model. The comparable performance of the post-treatment model in both samples 423 
indicates that the treatment related variables that were added to this model (number of oocytes, 424 
cryopreservation of embryos, and the number and stage of embryos) are important predictors for live birth 425 
after treatment. 426 
Other than the influence of overfitting, some key differences between the Dutch and UK healthcare 427 
systems may also have affected the models’ performance in this external validation study. An important 428 
factor is the reimbursement policy for fertility treatment. All Dutch infertile couples are insured for a 429 
minimum of three complete IVF/ICSI cycles. In contrast, most couples in the UK receive no standard 430 
funding for ART (Berg Brigham et al., 2013). Since IVF/ICSI treatment is expensive, this induces 431 
discrepancies in the patient population initiating and continuing treatment between the two study samples 432 
(Rajkhowa et al., 2006). As can be seen in the baseline table (Table I) and flowchart (Figure 1), couples 433 
in the UK had a longer average duration of infertility before starting treatment and were more likely to 434 
discontinue treatment after the first and second cycles than couples in the Netherlands. Also, the decrease 435 
in LBR is more evident in the UK than in the Netherlands over the first three cycles, which suggests that 436 
differences exist in both reasons for discontinuation as well as prognostic profiles of women 437 
discontinuing treatment in the two countries. These phenomena are, in part, financially driven, and could 438 
partially explain the difference in predictive ability of the UK models in the Dutch cohort.   439 
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Furthermore, despite the fact that the infertility guidelines of both countries include similar approaches 440 
for treatment of infertile couples, there are important variations in treatment characteristics between the 441 
two study samples (Dutch Society of Obstetrics and Gynaecology (NVOG), 2010; National Institute for 442 
Health and Care Excellence (NICE), 2013). Some of these differences are mainly due to changes in 443 
clinical practice over time. As is shown by the baseline table (Table 1), women in the more recent Dutch 444 
cohort (2011-2014) generally had a single embryo transfer in their first fresh treatment cycle, whereas 445 
women in the earlier UK cohort (1999-2009) most often had a double embryo transfer. Also, embryo 446 
cryopreservation was performed in over half of the Dutch women as compared to only a quarter of the 447 
women in the UK. Other differences are explained by variation in treatment protocols between 448 
geographic locations. For one, no blastocyst stage embryos transfers were performed in the Netherlands in 449 
contrast to the proportion of blastocyst stage embryo transfers in the UK of more than 10%. Also, Dutch 450 
women more frequently had no embryo available for transfer after their first treatment cycle, which is 451 
most likely caused by strict cancellation criteria particularly for hyper response. These differences in 452 
treatment characteristics suggest that the development sample does not fully reflect clinical practice in a 453 
more recent time period and in a different geographic context. As cumulative LBR are substantially 454 
affected by the variation in treatment characteristics (Glujovsky et al., 2016; Pandian et al., 2013; Wong 455 
et al., 2014), this could explain part of the different performance of the pre-treatment model in the 456 
validation sample . The stable performance of the post-treatment model, which includes embryo stage and 457 
embryo cryopreservation as important predictors, seems to confirm the impact of the variation in these 458 
variables on model performance.  459 
The addition of measures of ovarian reserve, i.e. AMH and AFC, and body weight to the McLernon 460 
prediction models revealed only a marginal improvement of model performance in the OPTIMIST 461 
dataset. The additional value of these tests can therefore be questioned, especially in view of the extra 462 
costs and physical burden on the patient. Female age is one of the most important predictors in the 463 
McLernon models (McLernon et al., 2016). As female age is correlated with the ovarian reserve, adding 464 
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AMH and AFC provides limited new information to the prediction models. This is in line with previous 465 
studies that showed that ovarian reserve tests have no added value to the use of female age alone in the 466 
prediction of ongoing pregnancy after treatment (Broer et al., 2013). Other potential predictors for live 467 
birth, such as ethnicity, smoking status and alcohol intake, were not included in this update of the 468 
McLernon model (Dhillon et al., 2015; Rossi et al., 2011; Waylen et al., 2009). The additional value of 469 
these variables for model performance was considered uncertain, as the reporting is remarkably subjective 470 
and/or often incomplete (Liber and Warner, 2018; Stockwell et al., 2016). 471 
Clinical implications 472 
Discrimination and calibration have been recognized as measures to evaluate the performance of 473 
prediction models (Altman et al., 2009; Steyerberg, 2009). However, the discriminative ability at the 474 
binary level of most prediction models in reproductive medicine, as expressed by the c-statistic, is 475 
considerably low (Leushuis et al., 2009). As at the moment of prediction the outcome of pregnancy has 476 
not yet occurred, the c-statistic is determined using the calculated probability of pregnancy. The 477 
maximum value of the c-statistic depends on the variability of these calculated probabilities in the 478 
infertile population. Since infertility is a complex and multifactorial health problem and due to the 479 
absence of strong predictors for live birth – particularly pre-treatment – , the probability distribution in 480 
infertile couples that have a live birth has a considerable overlap with the distribution of those without a 481 
live birth. Therefore the maximum c-statistic can be expected to be low (Cook, 2007; Coppus et al., 482 
2009), as is seen in the external validation of the pre-treatment model. However, this does not necessarily 483 
imply that such prediction models have limited use in clinical practice. Models with reliable predictions 484 
and a clinically useful distribution of probabilities for achieving a live birth, as assessed by calibration, 485 
can still support patients and clinicians in clinical decision making around infertility treatment (Coppus et 486 
al., 2009). 487 
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As the calibration plots of both the recalibrated pre-treatment model and the post-treatment model 488 
indicate accurate predictions with a useful range of prognoses, these models can be used within the 489 
Netherlands as counselling tools to complement clinical reasoning at two certain time points. Before 490 
initiating treatment, the recalibrated pre-treatment model offers couples and clinicians a personalised and 491 
objective estimate of success over multiple complete treatment cycles. And after the first fresh embryo 492 
transfer, the post-treatment model provides a revised estimate using treatment related information to 493 
personalize the predictions even more. Despite the applicability of the models as counselling tools to 494 
inform patients about their prognosis, the McLernon models should not yet be used for decisions on 495 
whether or not to withhold fertility treatment. The impact of such model-based decisions on cost-benefit 496 
outcomes should be investigated first and proven to be beneficial. To implement the McLernon models as 497 
counselling tools in other countries as well, national recalibration is recommended to account for 498 
geographical differences in IVF/ICSI treatment. 499 
The McLernon models were converted into an online calculator to facilitate the use of the models in 500 
clinical practice (https://w3.abdn.ac.uk/clsm/opis). As the original pre-treatment model overestimates 501 
cumulative LBR for couples in the Netherlands, conversion of the recalibrated pre-treatment model into a 502 
new online calculator is needed for implementation in Dutch clinical practice. This tailored online 503 
calculator can then provide accurate and up to date predictions for couples and clinicians in the 504 
Netherlands. Ultimately, the online calculator will be offered for implementation on the websites of the 505 
Dutch Patient Association for people with fertility problems ‘Freya’ and the Dutch Association of 506 
Obstetrics and Gynaecology (NVOG) to increase the accessibility of the models.  507 
Research implications 508 
Following this external validation study, future studies could focus on the impact of introducing the 509 
McLernon prediction models in clinical practice, and assess changes in patient and clinicians’ behaviour 510 
and its effects on LBR and cost-effectiveness.   511 
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In conclusion, after minor recalibration of the pre-treatment model, the McLernon models have proven to 512 
be valid in predicting the chance of cumulative live birth after multiple complete treatment cycles in 513 
another geographical context and in a more recent time period. Updating the models with AMH, AFC and 514 
body weight revealed only a marginal improvement of predictive performance. Following national 515 
recalibration, implementation of the McLernon models as counselling tools in clinical practice will 516 
provide infertile couples and clinicians with objective and personalized estimates of success over multiple 517 
complete IVF/ICSI cycles. 518 
  519 
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Figure legends 666 
Figure 1: Flow chart presenting the numbers (%) of live birth, treatment continuation and discontinuation 667 
over six complete cycles in the OPTIMIST and HFEA databases (McLernon et al., 2016).  668 
 669 
Figure 2: Calibration plots showing the association between the calculated and observed cumulative live 670 
birth rates over 3 complete IVF/ICSI cycles in the OPTIMIST cohort for a) the original pre-treatment 671 
model as described by McLernon et al (McLernon et al., 2016) b) recalibrated pre-treatment model with 672 
adjustment of the intercept.  673 
 674 
Figure 3: Calibration plot showing the association between the calculated and observed cumulative live 675 
birth rates over 3 complete IVF/ICSI cycles in the OPTIMIST cohort for the original post-treatment 676 
model as described by McLernon (McLernon et al., 2016). 677 
 678 
Figure 4:  Example of the recalibrated pre-treatment model predicting the cumulative probability of a 679 
live birth up to three complete ICSI cycles for a woman with primary infertility caused by a male factor, 680 
aged 30 or 40 years with an infertility duration of two or five years. 681 
 682 
Figure 5: Example of the with AMH, AFC and body weight updated pre-treatment model predicting the 683 
cumulative probability of a live birth up to three complete ICSI cycles for a woman with two years of 684 
primary infertility caused by a male factor, aged 30 or 40 years, a total body weight of 70 kilograms, with 685 
an AMH of 2.0 or 0.5 ng/mL and an AFC of 15 or 7.  686 
 687 
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Figure 6: Example of the post-treatment model predicting the cumulative probability of a live birth up to 688 
three complete ICSI cycles for a woman with two years of primary infertility caused by a male factor, 689 
aged 30 or 40 years, with 5 or 10 oocytes retrieved, a cleavage stage single embryo transfer, with or 690 
without embryo cryopreservation. 691 
 692 
Supplementary Figure 1. Plots showing the adjusted relation between the predictors included in the 693 
updated McLernon pre-treatment model and the probability of a live birth after IVF/ICSI treatment.  694 
Predictor; linear predictor (XB) of the original pre-treatment model as described by McLernon 695 
(McLernon et al. 2016), Weight; female body weight in kg, AFC; antral follicle count (2-10mm), AMH; 696 
anti-Müllerian hormone (ng/mL) 697 
 698 
Supplementary Figure 2. Plots showing the adjusted relation between the predictors in the updated 699 
McLernon post-treatment model and the probability of a live birth after IVF/ICSI treatment.  700 
Predictor: linear predictor (XB) of the original post-treatment model as described by McLernon 701 
(McLernon et al 2016); AFC; antral follicle count (2-10mm), AMH; anti-Müllerian hormone (ng/mL) 702 
 703 
 704 
 705 
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Figure 1: Flow chart presenting the numbers (%) of live birth, treatment continuation and discontinuation 
over six complete treatment cycles in the OPTIMIST and HFEA databases (McLernon et al., 2016).  
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Figure 4:  Example of the recalibrated pre-treatment model predicting the cumulative probability of live birth 
up to three complete ICSI cycles for a woman with primary infertility caused by a male factor, aged 30 or 40 
years with an infertility duration of two or five years.  
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Figure 5: Example of the with AMH, AFC and body weight updated pre-treatment model predicting the 
cumulative probability of  live birth up to three complete ICSI cycles for a woman with two years of primary 
infertility caused by a male factor, aged 30 or 40 years, a total body weight of 70 kilograms, with an AMH of 
2.0 or 0.5ng/mL and an AFC of 15 or 7.  
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Tables 
Table I Characteristics of patient and treatment variables included as predictors in the development 
sample (HFEA cohort) and the validation sample (OPTIMIST cohort) (McLernon et al., 2016). Unless 
stated otherwise data are n (%). 
Characteristics HFEA cohort OPTIMIST cohort Missing 
values in 
OPTIMIST 
cohort (%) 
No of women 113 873 1 511  
No of complete cycles 184 269 2 881  
    
Patient characteristics    
Age (years), mean (SD) 34.1 (5) 33.5 (5) 2 (0.1) 
Duration of infertility (years), median (IQR) 4 (3-6) 2 (2-3) 18 (1.2) 
No previous pregnancy in couple,   75 541 (66) 917 (61) 2 (0.1) 
Cause of infertility:    
- Tubal factor) 26 545 (23) 158 (11)  
- Male factor 49 753 (44) 839 (56)  
- Anovulatory  15 942 (14) NA by protocol  
- Endometriosis 7 590 (7) 60 (4)  
- Unexplained  32 693 (29) 521 (35) 
 
 
Body weight (kg), mean (SD) NA 69.5 (13) 36 (2.4) 
Anti-Müllerian hormone (ng/mL), median (IQR) NA 1.9 (1-3) 169 (11.2) 
Antral follicle count (2-10mm), median (IQR) NA 13 (9-18)  
 
 
   
Treatment characteristics of first completed 
cycle 
   
IVF 67 511 (59) 830 (55)  
ICSI 46 362 (41) 681 (45)  
No of oocytes retrieved, median (IQR) 8 (5-13) 8 (5-13)
a
 1 (0.1) 
No of embryos created, median (IQR) 5 (2-8) 4 (2-7)
a
 4 (0.3) 
No of embryos frozen, median (IQR) 0 (0-1) 1 (0-3)
a
 6 (0.5) 
Cryopreservation of embryos  28 950 (25) 726 (48)  
Fresh embryo transfer: stage and no. of 
transferred embryos: 
  24 (1.6) 
- Cleavage stage SET 9 248 (8) 1 004 (66)  
- Cleavage stage DET 75 701 (66) 125 (8)  
- Cleavage stage TET 8 649 (8) 4 (0.3)  
- Blastocyst stage SET 662 (1) NA  
- Blastocyst stage DET 2 960 (3) NA  
- Blastocyst stage TET) 130 (0.1) NA  
- No transfer 15 501 (14) 354 (23)  
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NA; not available, SET; single embryo transfer, DET; double embryo transfer, TET; triple embryo transfer. 
 a) Median is calculated over 1293 women who had an ovarian follicle aspiration. 
 
Page 41 of 48
http://humrep.oupjournals.org
Draft Manuscript Submitted to Human Reproduction for Peer Review
  
 
 
Supplementary Figure 1. Plots showing the adjusted relation between the predictors included in the updated 
McLernon pre-    treatment model and the probability of a live birth after IVF/ICSI treatment. Predictor; 
linear predictor (XB) of the original pre-treatment model as described by McLernon (McLernon et al. 2016), 
Weight; female body weight in kg, AFC; antral follicle count (2-10mm), AMH; anti-Müllerian hormone 
(ng/mL).  
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Supplementary Figure 2. Plots showing the adjusted relation between the predictors in the updated 
McLernon post-treatment model and the probability of a live birth after IVF/ICSI 
   treatment. Predictor: linear predictor (XB) of the original post-treatment model as described by 
McLernon (McLernon et al 2016); AFC; antral follicle count (2-10mm), AMH; anti-Müllerian hormone 
(ng/mL).  
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Supplementary text 1. McLernon pre-treatment model. 
 
 
Table showing the predictors in the original McLernon pre-treatment model (McLernon et al., 
2016). 
 
Name predictor Description Range of possible values 
Age Female age  18 to 50 years 
Duration How long have you been trying to conceive? 0 to 21 years 
Previous Have you been pregnant before? 1 = No;  0 = Yes 
Tubal Do you have a problem with your tubes? 1 = Yes; 0 = No 
Anovulation Do you have an ovulation problem? 1 = Yes; 0 = No 
MaleFactor Do you have a male factor fertility problem? 1 = Yes; 0 = No 
Unexplained Do you have an unexplained fertility problem? 1 = Yes; 0 = No 
Treatment Which fertility treatment are you planning on having? 1 = ICSI; 0 = IVF 
 
 
Original pre-treatment model formulas as described by McLernon et al. (McLernon et al., 2016). 
 
1. For the non-linear relation between Age and the probability of live birth, the following Age1, Age2 
and Age3 equations are first calculated and then used in the XB equation below (point 3). 
 
• Age1 = max((Age-26)/k,0)**3+(11*max((Age-41)/k,0)**3-(15)*max((Age-37)/k,0)**3)/4; 
• Age2 = max((Age -31)/k,0)**3+(6*max((Age -41)/k,0)**3-(10)*max((Age -37)/k,0)**3)/4; 
• Age3 = max((Age -34)/k,0)**3+(3*max((Age -41)/k,0)**3-(7)*max((Age -37)/k,0)**3)/4; 
k=15**(2/3); **means ‘to the power of’  
 
2. For the non-linear relation between Year and the probability live birth, the following Year1 and 
Year2 equations are first calculated and then used in the XB equation below (point 3). The value 
Year= 0 is used for the most up to date predictions.  
 
• Year1 = max((Year+9)/k,0)**3+((6)*max((Year)/k,0)**3-(9)*max((Year+3)/k,0)**3)/(3); 
• Year2 = max((Year+6)/k,0)**3+((3)*max((Year)/k,0)**3-(6)*max((Year+3)/k,0)**3)/(3); 
k= 9**(2/3). 
 
3. Calculate XB. 
 
XB =  -0.9948 + 0.0362
a
 + (0.0275*Age) + (-0.1805*Age1) + (0.4553*Age2) + (-1.1990*Age3) 
+ (-0.0295*Duration) + (-0.0772*Previous) + (-0.0957*Tubal) + (0.0492*Anovulation) + 
(-0.1005*MaleFactor) + (0.0602*Unexplained) + (0.2155*Treatment) + (0.0334*Year) + 
(-0.0370*Year1) + (0.2173*Year2).  
 
a) To inflate predictions to 2013 an additional 0.0362 is added. 
 
4. Calculate the predicted probability of live-birth after the first, second, …., sixth IVF cycle. 
 
PCycle1 = exp(XB)/(1+exp(XB)) 
PCycle2 = exp(XB - 0.2394)/(1+exp(XB - 0.2394)) 
PCycle3 = exp(XB - 0.4110)/(1+exp(XB - 0.4110)) 
PCycle4 = exp(XB - 0.5628)/(1+exp(XB - 0.5628)) 
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PCycle5 = exp(XB - 0.7189)/(1+exp(XB - 0.7189)) 
PCycle6 = exp(XB - 0.8138)/(1+exp(XB - 0.8138)) 
 
5. Calculate the predicted cumulative probability of a live-birth after 1, 2, 3,…., 6 completed IVF cycles: 
 
CumPCycle1 = 1-(1-p1) 
CumPCycle2 = 1-((1-p1)*(1-p2)) 
CumPCycle3 = 1-((1-p1)*(1-p2)*(1-p3)) 
CumPCycle4 = 1-((1-p1)*(1-p2)*(1-p3)*(1-p4)) 
CumPCycle5 = 1-((1-p1)*(1-p2)*(1-p3)*(1-p4)*(1-p5)) 
CumPCycle6 = 1-((1-p1)*(1-p2)*(1-p3)*(1-p4)*(1-p5)*(1-p6)) 
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Supplementary text 2. McLernon post-treatment model.  
 
 
Table showing the predictors in the original McLernon post-treatment model (McLernon et al., 
2016). 
 
Name 
predictor 
Description Range of possible values 
Age Female age  18 to 50 years 
Duration How long have you been trying to conceive? 0 to 21 years 
Previous Have you been pregnant before? 1 = No;  0 = Yes 
Tubal Do you have a problem with your tubes? 1 = Yes; 0 = No 
Eggs How many eggs were collected on your first IVF cycle? (1 to 28) 
Treat Was your first cycle IVF or ICSI? (1 = ICSI; 0 = IVF) 
Cryo In your first cycle did you have embryos frozen? (1 = Yes; 0 = No) 
Stage What type of embryo transfer did you have in your first 
fresh embryo transfer?  
(No embryos transferred;  
Single cleavage stage;  
Single blastocyst stage;  
Double cleavage stage;  
Double blastocyst stage;  
Triple cleavage stage; 
Triple blastocyst stage) 
 
 
Original post-treatment model formulas as described by McLernon et al. (McLernon et al., 2016): 
 
1. For the non-linear relation between Age and the probability of live birth, the following Age1, Age2 
and Age3 equations are first calculated and then used in the XB equation below (point 4): 
 
• Age1 = max((Age-26)/k,0)**3+(11*max((Age-41)/k,0)**3-(15)*max((Age-37)/k,0)**3)/4;  
• Age2 = max((Age -31)/k,0)**3+(6*max((Age -41)/k,0)**3-(10)*max((Age -37)/k,0)**3)/4;  
• Age3 = max((Age -34)/k,0)**3+(3*max((Age -41)/k,0)**3-(7)*max((Age -37)/k,0)**3)/4;  
k=15**(2/3), **means ‘to the power of’  
 
2. For the non-linear relation between Year and the probability of live birth, the following Year1 
equation is first calculated and then used in the XB equation below (point 4). The value Year = 0 is 
used for the most up to date predictions.  
 
• Year1 = max((Year+8)/k,0)**3+((4)*max((Year+1)/k,0)**3-(7)*max((Year+4)/k,0)**3)/(3);  
k= 7**(2/3).  
 
3. For the non-linear relation between Eggs and the probability of live birth, the following Eggs1 
equation is first calculated and then used in the XB equation below (point 4):  
 
• Eggs1=max((Eggs-3)/k,0)**3+((6)*max((Eggs-18)/k,0)**3-(15)*max((Eggs-9)/k,0)**3)/(9);  
k= 15**(2/3). 
 
4. Calculate XB  
 
XB =  -1.7564 + 0.0362
a
 + (0.0272*Age) + (-0.1556*Age1) + (0.3812*Age2) + (-1.0184*Age3) 
+ (-0.0208*Duration) + (-0.0504*Previous) + (-0.2207*Tubal) + (0.0018*Year) + 
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(0.0619*Year1) + (0.0630*Eggs) + (-0.0479*Eggs1) + (-0.0968*Treat) + (0.6490*Cryo) 
+ Stage
b 
 
a) To inflate predictions to 2013 an additional 0.0362 is added. 
b) Stage equals the following values depending on group chosen:  
If Double cleavage stage then Stage=0;  
If No embryos transferred then Stage= -1.0842;  
If Single cleavage stage then Stage= -0.5675;  
If Single blastocyst stage then Stage= 0.0684;  
If Double blastocyst stage then Stage= 0.5802;  
If Triple cleavage stage then Stage= 0.0218;  
If Triple blastocyst stage then Stage= 0.4547.  
 
 
1. Calculate the predicted probability of live-birth after the first, second, …., sixth IVF cycle: 
 
PCycle1 = exp(XB)/(1+exp(XB))  
PCycle2 = exp(XB - 0.1933)/(1+exp(XB - 0.1933))  
PCycle3 = exp(XB - 0.3537)/(1+exp(XB - 0.3537))  
PCycle4 = exp(XB - 0.5122)/(1+exp(XB - 0.5122))  
PCycle5 = exp(XB - 0.6788)/(1+exp(XB - 0.6788))  
PCycle6 = exp(XB - 0.7666)/(1+exp(XB - 0.7666))  
 
2. Calculate the predicted cumulative probability of a live-birth after 1, 2, 3,…., 6 complete IVF cycles: 
 
CumPCycle1 = 1-(1-p1)  
CumPCycle2 = 1-((1-p1)*(1-p2))  
CumPCycle3 = 1-((1-p1)*(1-p2)*(1-p3))  
CumPCycle4 = 1-((1-p1)*(1-p2)*(1-p3)*(1-p4))  
CumPCycle5 = 1-((1-p1)*(1-p2)*(1-p3)*(1-p4)*(1-p5))  
CumPCycle6 = 1-((1-p1)*(1-p2)*(1-p3)*(1-p4)*(1-p5)*(1-p6)) 
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Supplementary Text 3. Recalibrated pre-treatment model. 
 
 
Recalibrated pre-treatment model formula 
 
The included predictors and formulas 1, 2, 4 and 5 are unchanged to the original McLernon pre-
treatment model (see Supplementary Text 1) 
 
3. Calculate XB. 
 
XB =  - 0.3474
a
  - 0.9948 + 0.0362
b
 + (0.0275*Age) + (-0.1805*Age1) + (0.4553*Age2) +  
(-1.1990*Age3) + (-0.0295*Duration) + (-0.0772*Previous) + (-0.0957*Tubal) + 
(0.0492*Anovulation) + (-0.1005*MaleFactor) + (0.0602*Unexplained) + 
(0.2155*Treatment) + (0.0334*Year) + (-0.0370*Year1) + (0.2173*Year2).  
 
a) To recalibrate the pre-treatment model, 0.3474 is subtracted from the intercept. 
b) To inflate predictions to 2013 an additional 0.0362 is added. 
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